Sugi Predict

Sugi Predict / Compounds / SCHEMBL4091971

SCHEMBL4091971

SCHEMBL4091971

CC(C)(C)c1ccc(N(Cc2ccc(C(=O)Nc3nn[nH]n3)cc2)C(=O)Nc2cccc(S(C)(=O)=O)c2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GCGR P47871 14/20 0.51
▸ CA1 P00915 1/20 0.45
▸ CA2 P00918 1/20 0.45
▸ GIPR P48546 4/20 0.44
▸ RAB9A P51151 2/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ NR1H4 Q96RI1 1/20 0.43
▸ ADCY6 O43306 1/20 0.43
▸ ADCY3 O60266 1/20 0.43
▸ ADCY9 O60503 1/20 0.43
▸ ADCY5 O95622 1/20 0.43
▸ ADCY8 P40145 1/20 0.43
▸ ADCY7 P51828 1/20 0.43
▸ ADCY2 Q08462 1/20 0.43
▸ ADCY1 Q08828 1/20 0.43
▸ ADCY4 Q8NFM4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4092081 0.94 GCGR (0.51) GCGRCA1CA2GIPRRAB9A
SCHEMBL4097893 0.92 GCGR (0.50) GCGRCA1CA2GIPRRAB9A
SCHEMBL4085611 0.89 KDM4E (0.43) GCGRGIPRRAB9APTGDR2NPC1
SCHEMBL4096573 0.89 GCGR (0.57) GCGRGIPRGLP1R
SCHEMBL4081406 0.89 GCGR (0.54) GCGRGIPRMEN1KMT2ANR1H4
SCHEMBL4081619 0.88 PTGDR2 (0.43) GCGRGIPRMEN1ALDH1A1KMT2A
SCHEMBL13799996 0.88 LMNA (0.55) GCGRGIPRRAB9AMEN1ALDH1A1
SCHEMBL2660233 0.88 GCGR (0.53) GCGRGIPRNR1H4ADCY6ADCY3
SCHEMBL13813564 0.88 GCGR (0.53) GCGRGIPRNR1H4ADCY6ADCY3
SCHEMBL4082060 0.88 GCGR (0.53) GCGRGIPRNR1H4GCG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 — — US disclosed
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 — — US disclosed
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 — — US disclosed
EP-1183229-B1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK AS (DK) 2005-10-26 — — EP disclosed
US-20050203108-A1 Glucagon antagonists/inverse agonists PFIZER INC 2005-09-15 — — US disclosed
US-6875760-B2 Glucagon antagonists/inverse agonists NOVO NORDISK A/S (DK) 2005-04-05 — — US disclosed
US-20030220350-A1 Glucagon antagonists/inverse agonists PFIZER INC 2003-11-27 — — US disclosed
US-6503949-B1 Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity NORO NORDISK A/S (DK) 2003-01-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203108-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR GCGR 3/4885CA1 4464/4885CA2 3233/4885
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists GLP1R, GPR119, GCGR GCGR 3/4885CA1 4464/4885CA2 3233/4885
US-20030220350-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR GCGR 3/4885CA1 4464/4885CA2 3233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.